Ruby Nanomed
Braga
About Ruby Nanomed
RUBYnanomed provides non-invasive monitoring of cancer progression. They enable the analysis of their phenotypic, genetic, and functional characteristics, facilitating unprecedentedly frequent monitoring of cancer progression in a minimally invasive, cost-efficient way. They enable oncologists to detect and analyze the evolution of cancer subtypes and therapeutic resistance mechanisms in each patient, providing personalized therapy insights to treat their patients.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $3.1M
- Funding stage: Seed
- Last round: Seed (Aug 2023)
- Website: rubynanomed.com
- Phone: +351 253 654 985
Industries & Categories
Health Care
Social Profiles
Canonical: https://fsome.com/organization/ruby-nanomed-103173 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.